These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 33641217)

  • 1. Comprehensive Review of Molecular Mechanisms and Clinical Features of Invasive Lobular Cancer.
    Pramod N; Nigam A; Basree M; Mawalkar R; Mehra S; Shinde N; Tozbikian G; Williams N; Majumder S; Ramaswamy B
    Oncologist; 2021 Jun; 26(6):e943-e953. PubMed ID: 33641217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invasive ductal carcinoma with lobular features: a comparison study to invasive ductal and invasive lobular carcinomas of the breast.
    Arps DP; Healy P; Zhao L; Kleer CG; Pang JC
    Breast Cancer Res Treat; 2013 Apr; 138(3):719-26. PubMed ID: 23535842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade.
    Metzger-Filho O; Ferreira AR; Jeselsohn R; Barry WT; Dillon DA; Brock JE; Vaz-Luis I; Hughes ME; Winer EP; Lin NU
    Oncologist; 2019 Jul; 24(7):e441-e449. PubMed ID: 30518616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
    Zhao H
    Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast.
    Zengel B; Yararbas U; Duran A; Uslu A; Elıyatkın N; Demırkıran MA; Cengiz F; Şimşek C; Postacı H; Vardar E; Durusoy R
    Breast Cancer; 2015 Jul; 22(4):374-81. PubMed ID: 23925582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lobular Histology Does Not Predict the Need for Axillary Dissection Among ACOSOG Z0011-Eligible Breast Cancers.
    Mamtani A; Zabor EC; Stempel M; Morrow M
    Ann Surg Oncol; 2019 Oct; 26(10):3269-3274. PubMed ID: 31342363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive lobular carcinoma: an understudied emergent subtype of breast cancer.
    Mouabbi JA; Hassan A; Lim B; Hortobagyi GN; Tripathy D; Layman RM
    Breast Cancer Res Treat; 2022 Jun; 193(2):253-264. PubMed ID: 35347549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
    Lips EH; Mukhtar RA; Yau C; de Ronde JJ; Livasy C; Carey LA; Loo CE; Vrancken-Peeters MJ; Sonke GS; Berry DA; Van't Veer LJ; Esserman LJ; Wesseling J; Rodenhuis S; Shelley Hwang E;
    Breast Cancer Res Treat; 2012 Nov; 136(1):35-43. PubMed ID: 22961065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
    Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
    Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy.
    Wong H; Lau S; Cheung P; Wong TT; Parker A; Yau T; Epstein RJ
    BMC Cancer; 2014 Nov; 14():826. PubMed ID: 25385074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology.
    Moran MS; Yang Q; Haffty BG
    Breast J; 2009; 15(6):571-8. PubMed ID: 19995377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.
    Truin W; Roumen RMH; Siesling S; van de Vijver KK; Tjan-Heijnen VCG; Voogd AC
    Breast Cancer Res Treat; 2017 Jul; 164(1):133-138. PubMed ID: 28365833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lobular-Like Features and Outcomes of Mixed Invasive Ductolobular Breast Cancer (MIDLC): Insights from 54,403 Stage I-III MIDLC Patients.
    Lohani KR; Hoskin TL; Day CN; Yasir S; Boughey JC; Degnim AC
    Ann Surg Oncol; 2024 Feb; 31(2):936-946. PubMed ID: 37872454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Long-term Study of a Large Series of Patients with Invasive Ductal Carcinoma and Invasive Lobular Carcinoma. Loco-Regional Recurrence, Metastasis, and Survival.
    García-Fernández A; Lain JM; Chabrera C; García Font M; Fraile M; Barco I; Torras M; Reñe A; González S; González C; Piqueras M; Veloso E; Cirera L; Pessarrodona A; Giménez N
    Breast J; 2015; 21(5):533-7. PubMed ID: 26190560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study.
    Wang K; Zhu GQ; Shi Y; Li ZY; Zhang X; Li HY
    Clin Breast Cancer; 2019 Feb; 19(1):e101-e115. PubMed ID: 30502219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
    Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
    Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer.
    Oesterreich S; Nasrazadani A; Zou J; Carleton N; Onger T; Wright MD; Li Y; Demanelis K; Ramaswamy B; Tseng G; Lee AV; Williams N; Kruse M
    J Natl Cancer Inst; 2022 Nov; 114(11):1511-1522. PubMed ID: 36239760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR expression in invasive breast carcinoma and its effect on adenovirus transduction efficiency.
    Phung AT; Shah JR; Dong T; Reid T; Larson C; Sanchez AB; Oronsky B; Trogler WC; Kummel AC; Aisagbonhi O; Blair SL
    Breast Cancer Res; 2024 Sep; 26(1):131. PubMed ID: 39256827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB).
    Rothschild HT; Clelland EN; Abel MK; Chien AJ; Shui AM; Esserman L; Khan SA; Mukhtar RA
    Breast Cancer Res Treat; 2024 Jan; 203(2):245-256. PubMed ID: 37833450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer.
    Truin W; Vugts G; Roumen RM; Maaskant-Braat AJ; Nieuwenhuijzen GA; van der Heiden-van der Loo M; Tjan-Heijnen VC; Voogd AC
    Ann Surg Oncol; 2016 Jan; 23(1):51-7. PubMed ID: 25980321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.